Clients

Galectin Therapeutics Inc.

Company Snapshot: Galectin Therapeutics Inc.

GALT
Last Change Volume High Low

Company Overview

Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.

Client News

  1. May 23 2022 Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress
  2. May 16 2022 Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
  3. Apr 14 2022 Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
  4. Mar 31 2022 Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update